Target Information

Target General Infomation
Target ID
T57361
Former ID
TTDR00005
Target Name
Kallikrein
Target Type
Successful
Disease Peptic ulcer [ICD9: 531-534; ICD10: K25-K27]
Retinal venous occlusion [ICD10: H34.8]
Target Validation
T57361
Drugs and Mode of Action
Drug(s) Cetraxate Drug Info Approved Peptic ulcer [551871]
Ecallantide Drug Info Approved Retinal venous occlusion [522774], [541991]
Modulator Cetraxate Drug Info [533503], [551871]
Inhibitor Ecallantide Drug Info [536771]
Peptide boronate Drug Info [533716]
References
Ref 522774ClinicalTrials.gov (NCT00969293) Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion. U.S. National Institutes of Health.
Ref 541991(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6955).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 533503A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
Ref 533716J Med Chem. 1995 Apr 28;38(9):1511-22.Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.
Ref 536771Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.